Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

A new target for Alzheimer's disease: A small molecule SERCA activator is neuroprotective in vitro and improves memory and cognition in APP/PS1 mice.

Krajnak K, Dahl R.

Bioorg Med Chem Lett. 2018 May 15;28(9):1591-1594. doi: 10.1016/j.bmcl.2018.03.052. Epub 2018 Mar 21.

PMID:
29602679
2.

Small molecule SUMOylation activators are novel neuroprotective agents.

Krajnak K, Dahl R.

Bioorg Med Chem Lett. 2018 Feb 1;28(3):405-409. doi: 10.1016/j.bmcl.2017.12.028. Epub 2017 Dec 13.

PMID:
29269215
3.

Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor.

Pinkerton AB, Sergienko E, Bravo Y, Dahl R, Ma CT, Sun Q, Jackson MR, Cosford NDP, Millán JL.

Bioorg Med Chem Lett. 2018 Jan 1;28(1):31-34. doi: 10.1016/j.bmcl.2017.11.024. Epub 2017 Nov 11.

4.

A new target for Parkinson's disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats.

Dahl R.

Bioorg Med Chem. 2017 Jan 1;25(1):53-57. doi: 10.1016/j.bmc.2016.10.008. Epub 2016 Oct 12.

PMID:
27776889
5.

Cytoprotective small molecule modulators of endoplasmic reticulum stress.

Munshi S, Dahl R.

Bioorg Med Chem. 2016 Jun 1;24(11):2382-8. doi: 10.1016/j.bmc.2016.03.045. Epub 2016 Mar 29. Review.

PMID:
27091069
6.

Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders.

Kang S, Dahl R, Hsieh W, Shin A, Zsebo KM, Buettner C, Hajjar RJ, Lebeche D.

J Biol Chem. 2016 Mar 4;291(10):5185-98. doi: 10.1074/jbc.M115.705012. Epub 2015 Dec 23.

7.

Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure.

Kho C, Lee A, Jeong D, Oh JG, Gorski PA, Fish K, Sanchez R, DeVita RJ, Christensen G, Dahl R, Hajjar RJ.

Nat Commun. 2015 Jun 12;6:7229. doi: 10.1038/ncomms8229.

8.

Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis.

Musumeci L, Kuijpers MJ, Gilio K, Hego A, Théâtre E, Maurissen L, Vandereyken M, Diogo CV, Lecut C, Guilmain W, Bobkova EV, Eble JA, Dahl R, Drion P, Rascon J, Mostofi Y, Yuan H, Sergienko E, Chung TD, Thiry M, Senis Y, Moutschen M, Mustelin T, Lancellotti P, Heemskerk JW, Tautz L, Oury C, Rahmouni S.

Circulation. 2015 Feb 17;131(7):656-68. doi: 10.1161/CIRCULATIONAHA.114.010186. Epub 2014 Dec 17.

9.

Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.

Bravo Y, Teriete P, Dhanya RP, Dahl R, Lee PS, Kiffer-Moreira T, Ganji SR, Sergienko E, Smith LH, Farquharson C, Millán JL, Cosford ND.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4308-11. doi: 10.1016/j.bmcl.2014.07.013. Epub 2014 Jul 15.

10.

Alamar blue reagent interacts with cell-culture media giving different fluorescence over time: potential for false positives.

Munshi S, Twining RC, Dahl R.

J Pharmacol Toxicol Methods. 2014 Sep-Oct;70(2):195-8. doi: 10.1016/j.vascn.2014.06.005. Epub 2014 Jun 13.

PMID:
24933394
11.

Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.

Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.

J Med Chem. 2014 May 22;57(10):4154-72. doi: 10.1021/jm5000563. Epub 2014 May 9.

12.

Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.

Barile E, Wang S, Das SK, Noberini R, Dahl R, Stebbins JL, Pasquale EB, Fisher PB, Pellecchia M.

ChemMedChem. 2014 Jul;9(7):1403-12. doi: 10.1002/cmdc.201400067. Epub 2014 Mar 26.

13.

A 2nd Selective Inhibitor of Plasmodium falciparum Glucose-6-Phosphate Dehydrogenase (PfG6PDH) - Probe 2.

Maloney P, Hedrick M, Peddibhotla S, Hershberger P, Milewski M, Gosalia P, Li L, Preuss J, Sugarman E, Hood B, Suyama E, Nguyen K, Vasile S, Sergienko E, Salanawil S, Stonich D, Su Y, Dahl R, Mangravita-Novo A, Vicchiarelli M, McAnally D, Smith LH, Roth G, Diwan J, Chung TDY, Pinkerton AB, Bode L, Becker K.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Mar 28 [updated 2013 Mar 14].

14.

Discovery of enzyme modulators via high-throughput time-resolved FRET in living cells.

Gruber SJ, Cornea RL, Li J, Peterson KC, Schaaf TM, Gillispie GD, Dahl R, Zsebo KM, Robia SL, Thomas DD.

J Biomol Screen. 2014 Feb;19(2):215-22. doi: 10.1177/1087057113510740.

15.

Identification of a selective inhibitor of murine intestinal alkaline phosphatase (ML260) by concurrent ultra-high throughput screening against human and mouse isozymes.

Ardecky RJ, Bobkova EV, Kiffer-Moreira T, Brown B, Ganji S, Zou J, Pass I, Narisawa S, Iano FG, Rosenstein C, Cheltsov A, Rascon J, Hedrick M, Gasior C, Forster A, Shi S, Dahl R, Vasile S, Su Y, Sergienko E, Chung TDY, Kaunitz J, Hoylaerts MF, Pinkerton AB, Millán JL.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):1000-1004. doi: 10.1016/j.bmcl.2013.12.043. Epub 2013 Dec 19.

16.

A Selective Murine Intestinal Alkaline Phosphatase (muIAP) Inhibitor.

Ganji S, Zou J, Brown B, Bobkova EV, Ardecky R, Rosenstein C, Pass I, Dahl R, Vasile S, Sergienko E, Shi S, Stonich D, Cheltov A, Su Y, Mangravita-Novo A, Vicchiarelli M, McAnally D, Kim S, Nguyen H, Moreira TK, Smith LH, Zeng FY, Diwan J, Chung TDY, Pinkerton AB, Kaunitz J, Millán JL.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Oct 31 [updated 2013 Mar 7].

17.

A Selective Inhibitor of Plasmodium falciparum Glucose-6-Phosphate Dehydrogenase (PfG6PDH).

Maloney P, Hedrick M, Peddibhotla S, Hershberger P, Milewski M, Gosalia P, Li L, Preuss J, Sugarman E, Hood B, Suyama E, Nguyen K, Vasile S, Sergienko E, Salanawil S, Stonich D, Su Y, Dahl R, Mangravita-Novo A, Vicchiarelli M, McAnally D, Smith LH, Roth G, Diwan J, Chung TDY, Pinkerton AB, Bode L, Becker K.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Dec 16 [updated 2013 Mar 7].

18.

Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.

Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.

J Med Chem. 2012 Nov 26;55(22):9434-45. doi: 10.1021/jm3005306. Epub 2012 Oct 23.

19.

High-throughput FRET assay yields allosteric SERCA activators.

Cornea RL, Gruber SJ, Lockamy EL, Muretta JM, Jin D, Chen J, Dahl R, Bartfai T, Zsebo KM, Gillispie GD, Thomas DD.

J Biomol Screen. 2013 Jan;18(1):97-107. doi: 10.1177/1087057112456878. Epub 2012 Aug 24.

20.

Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification.

Kiffer-Moreira T, Yadav MC, Zhu D, Narisawa S, Sheen C, Stec B, Cosford ND, Dahl R, Farquharson C, Hoylaerts MF, Macrae VE, Millán JL.

J Bone Miner Res. 2013 Jan;28(1):81-91. doi: 10.1002/jbmr.1733.

Supplemental Content

Loading ...
Support Center